Clinical ophthalmology (Auckland, N.Z.)Oct 17, 2026

Semaglutide use and risk of diabetic eye disease and optic nerve damage in type 2 diabetes

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Oct 18, 2026

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide, are associated with improvements in glycemic control and weight loss in type 2 diabetes mellitus.

GLP-1RAs may improve blood sugar levels in individuals with type 2 diabetes.
These medications could lead to weight loss as a secondary benefit.
Concerns exist regarding a potential link between GLP-1RAs and non-arteritic anterior ischemic optic neuropathy (NAION).
The nature of the relationship between GLP-1RAs and NAION is currently uncertain.

Simplified

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), including semaglutide, are increasingly adopted for type 2 diabetes mellitus (T2DM) due to improvements in glycemic control and weight loss. Although concerns have been raised about a potential association with non-arteritic anterior ischemic optic neuropathy (NAION), this relationship remains uncertain.

Full Text

Full text is available at the source.

View Full Text ↗

Semaglutide use and risk of diabetic eye disease and optic nerve damage in type 2 diabetes

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief